Carl Zeiss Meditec Faces Crucial Test with Upcoming Interim Report

Carl Zeiss Meditec's shares are down 37% YTD. Investors await May 12 half-year results for a new outlook after a tough Q1 with a sharp EBITA decline.

Investors in Carl Zeiss Meditec are looking ahead to a pivotal mid-May date, as the medical technology firm prepares to release its half-year figures and provide a clearer picture of its ongoing challenges. The company’s shares, which have declined approximately 37% since the start of the year, are under significant pressure following a difficult first quarter.

A Challenging Quarter Sets the Stage

The initial period of the 2025/26 fiscal year proved particularly tough for the company. Revenue fell to 467 million euros, marking a 4.8% decrease compared to the prior year. More strikingly, the operating result (EBITA) experienced a severe contraction, dropping from 35.2 million euros to just 8.1 million euros. Management attributed this performance to a combination of adverse currency effects, an unfavorable product mix, and subdued investment sentiment in two of its key markets: the United States and China. In response to these headwinds, the company suspended its original annual forecast in January, which had projected revenue of 2.3 billion euros with an EBITA margin of 12.5%.

Analyst Perspective and Structural Headwinds

In late March, analysts at RBC Capital Markets reflected the prevailing caution by assigning Carl Zeiss Meditec a "Sector Perform" rating, accompanied by a price target of 32 euros. Analyst Jack Reynolds-Clark indicated that he does not anticipate the stock outperforming the market until the company resolves its operational issues.

A primary structural concern remains the Chinese market. The shift toward volume-based procurement tenders for intraocular lenses has dramatically intensified pricing pressure. In a strategic move to protect profitability, Carl Zeiss Meditec has withdrawn from certain tender processes. This decision, while defending margins, comes at the short-term cost of lost revenue. Conversely, RBC assesses the risk from the Middle East conflict as manageable, noting that the region contributes only 2 to 3 percent of total group sales.

All Eyes on May 12th

The publication of the half-year results on May 12, 2026, is now viewed as a critical milestone. The company’s management has committed to presenting an updated annual outlook alongside specific restructuring measures at that time. For shareholders, the report will serve as a key indicator of whether recently implemented cost-reduction initiatives and product localization strategies in growth markets are beginning to yield measurable results, or if further strategic adjustments are required.